Pulse Biosciences, Inc - PLSE STOCK NEWS

Pulse Biosciences (PLSE) reported Q3 2024 financial results and business updates. The company placed nsPFA Percutaneous Electrode Systems at seven U.S. sites and treated 9 patients in their atrial fibrillation study. They also treated over 50 patients with their nano-PFA 360° Cardiac Catheter. Financial highlights include GAAP costs of $13.7M (up from $11.3M YoY), GAAP net loss of $12.7M (vs $10.6M YoY), and cash position of $79.0M as of September 30, 2024. The company raised $60M through a rights offering in July 2024, with potential for additional $66M through warrant exercises.

Pulse Biosciences (PLSE) has appointed Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and added Dr. Andrea Natale as a medical advisor. Dr. Kenigsberg, founder of Florida Heart Rhythm Specialists, joins to support the development of the company's nano-PFA 360 Cardiac Catheter. Dr. Natale, Executive Medical Director of Texas Cardiac Arrhythmia Institute, will join existing advisors Dr. Vivek Reddy and Dr. Jacob Koruth to advance the clinical development of the catheter technology for treating atrial fibrillation.

Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its plans to release third quarter 2024 financial results on Wednesday, October 30, 2024, after the market closes. The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day to discuss the results.

Investors can participate in the call by dialing 1-877-407-0752 (domestic) or 1-201-389-0912 (international). Additionally, a live and recorded webcast of the event will be available on the company's investor relations website at http://investors.pulsebiosciences.com/.

Pulse Biosciences (Nasdaq: PLSE) reported business updates and preliminary Q2 2024 financial results. Key highlights include:

1. Completed first soft tissue ablation procedures in the US using the Percutaneous Electrode System.

2. Performed initial epicardial ablations for atrial fibrillation treatment in Europe.

3. Expanded enrollment for the endocardial ablation study.

4. Raised $60 million through a rights offering.

5. Q2 2024 financials: $11.7 million in GAAP costs and expenses, $9.4 million in non-GAAP costs and expenses, and $26.2 million in cash and equivalents as of June 30, 2024.

6. Granted inducement options to new employees totaling 215,000 shares.

Pulse Biosciences (Nasdaq: PLSE) has appointed Paul A. LaViolette to its Board of Directors as Co-Chairman alongside Robert W. Duggan. LaViolette brings 40 years of medical technology development, operating, and leadership expertise to the company, which specializes in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. His extensive experience includes roles as Chief Operating Officer at Boston Scientific and current positions as Managing Partner at SV Health Investors and director for Edwards Lifesciences. LaViolette's appointment is expected to provide valuable insights and expertise to help Pulse Biosciences develop transformational treatments and maximize the potential of its proprietary technology across various therapeutic categories.

Pulse Biosciences (NASDAQ: PLSE) has announced the successful treatment of the first two patients in a first-in-human feasibility study using its novel Cardiac Surgery System for atrial fibrillation. The procedure, performed at St. Antonius Hospital in the Netherlands, utilized the company's proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. The study will include up to 30 patients and aims to demonstrate the device's safety, effectiveness, and durability.

Key highlights:

• The system received FDA Breakthrough Device Designation in July 2024
• It was recently enrolled in the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP)
• Pulse Biosciences plans to pursue FDA premarket approval (PMA) for commercialization
• A pivotal clinical study is expected to begin in early 2025

Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in two upcoming investor conferences. The company will attend the 9th Annual Needham MedTech & Diagnostics 1x1 Conference virtually on August 13, 2024, hosting one-on-one meetings without a formal presentation. Additionally, Pulse Biosciences management will present at the Canaccord Genuity Annual Growth Conference in Boston on August 14, 2024, at 8:00am ET. A live and recorded webcast of the Canaccord presentation will be available on the company's investor relations website.

Pulse Biosciences (Nasdaq: PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its plans to release second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day to discuss the results. Investors can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international). A live and recorded webcast of the event will also be available on the company's investor relations website.

Pulse Biosciences has received FDA Breakthrough Device Designation for its CellFX® nsPFA Cardiac Surgery System, intended for treating atrial fibrillation (AF). The system uses proprietary nanosecond Pulsed Field Ablation™ technology, featuring a surgical clamp that delivers rapid, consistent ablation lesions during cardiac procedures. This approach is significantly faster and potentially safer than current thermal ablation methods, minimizing risk to surrounding tissues.

The designation facilitates expedited development and review processes by the FDA. Pulse Biosciences plans to pursue Premarket Approval (PMA) for commercialization in the U.S. and expects to start its pivotal clinical trial in 2025, with initial human procedures slated for later this year in the Netherlands.

This milestone underscores the technology's promise as a safer and more effective AF treatment, aiming for faster market introduction and improved patient outcomes.